3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance

Post-Intubation Sedation, Analgesia & Dissociative Maintenance

Securing the endotracheal tube is only the first step in emergency airway management. Once intubation is confirmed, critical care transport paramedics must immediately transition to post-intubation maintenance care. Endotracheal tubes, mechanical ventilation, and transport vibration cause significant pain, anxiety, and ventilator dyssynchrony. Providing structured analgosedation (analgesia-first sedation) is essential to ensure patient safety, maintain oxygenation, and prevent accidental extubation.

---

1. Analgosedation Philosophy & Avoiding Awareness Under Paralysis

The Analgosedation Paradigm

Historical critical care practice relied heavily on hypnotic sedatives (e.g., midazolam or propofol) as primary post-intubation agents. Modern critical care transport guidelines mandate an analgesia-first approach. Endotracheal intubation is intensely painful. Treating pain first with continuous IV opioids significantly reduces agitation, lowers total sedative consumption, shortens mechanical ventilation duration, and decreases ICU delirium.

Prevention of Patient Awareness Under Neuromuscular Blockade

One of the most severe clinical errors in emergency care is allowing a patient's sedation to wear off while neuromuscular blockade persists. Neuromuscular blocking agents (rocuronium, vecuronium) provide zero sedation, analgesia, or amnesia.

If paralytic activity outlasts induction hypnosis (e.g., etomidate lasting 10 minutes while rocuronium lasts 60 minutes), the patient experiences total motor paralysis while fully conscious—a state of intense horror and psychological trauma leading to post-traumatic stress disorder (PTSD). Physiological indicators of awareness under paralysis include:

• Unexplained sinus tachycardia and hypertension.
• Lacrimation (tearing) and diaphoresis.
• Mydriasis (pupillary dilation).
• Sudden spikes in ventilator peak airway pressures due to chest wall muscle tension.

Rule of Practice: Never administer a long-acting neuromuscular blocker without immediately initiating a continuous analgesic and sedative infusion.

---

2. Objective Sedation & Pain Assessment Scales

Titration of post-intubation infusions must be guided by objective, validated scoring systems rather than arbitrary dose administration.

Richmond Agitation-Sedation Scale (RASS)

The RASS is a 10-point scale evaluating patient agitation and depth of sedation:

Transport Target: Maintain most mechanical ventilation patients at a RASS of -2 to -3. Deep sedation (RASS -4 to -5) is reserved for severe ARDS requiring prone positioning, status epilepticus, or active neuromuscular blockade.

Behavioral Pain Scale (BPS)

Used for assessing pain in uncommunicative, intubated patients based on three physiological domains (Score 3 to 12):

1. Facial Expression: Relaxed (1), Partially tightened (2), Fully tightened (3), Grimacing (4).
2. Upper Limbs: No movement (1), Partially bent (2), Fully bent with finger flexion (3), Permanently retracted (4).
3. Compliance with Ventilator: Tolerating movement (1), Coughing but tolerating (2), Fighting ventilator (3), Inability to control ventilation (4).

• Clinical Target: BPS $< 5$ indicates adequate analgesia.

---

3. Continuous Infusion Pharmacology

Fentanyl Citrate

• Role: Primary Continuous Analgesic.
• Continuous Infusion Dose: $25 - 100\text{ mcg/hr}$ (or $0.5 - 2.0\text{ mcg/kg/hr}$). Bolus doses of $25 - 50\text{ mcg}$ IV every 15 minutes for breakthrough pain.
• Advantages: Hemodynamically stable, rapid onset, lacks histamine release (unlike morphine), does not cause hypotension in normovolemic patients.

Propofol (Diprivan)

• Role: Primary Sedative-Hypnotic.
• Continuous Infusion Dose: $5 - 50\text{ mcg/kg/min}$ (Titrate by $5-10\text{ mcg/kg/min}$ every 5 minutes to target RASS).
• Advantages: Ultra-short lipophilic elimination half-life allows rapid awakening for serial neurological exams.
• Adverse Effects: Profound arterial hypotension. Prolonged high-dose infusions ($> 4.0\text{ mg/kg/hr}$ or $> 67\text{ mcg/kg/min}$ for $> 48\text{ hours}$) can trigger Propofol Infusion Syndrome (PRIS), characterized by metabolic acidosis, hyperkalemia, rhabdomyolysis, hepatomegaly, acute kidney injury, and refractory bradycardic cardiac failure.

Ketamine (Ketalar)

• Role: Dissociative Analgesic & Sedative Infusion.
• Continuous Infusion Dose: $0.5 - 2.0\text{ mg/kg/hr}$ (sub-anesthetic analgesic rate $0.15 - 0.3\text{ mg/kg/hr}$; dissociative rate $> 1.0\text{ mg/kg/hr}$).
• Advantages: Maintains systemic vascular resistance and blood pressure, acts as a potent bronchodilator, and reduces opioid requirements.
• Indications: Severe asthma, COPD, septic shock, and patients with refractory pain.

Midazolam (Versed)

• Role: Benzodiazepine Sedative Infusion.
• Continuous Infusion Dose: $1 - 5\text{ mg/hr}$ (or $0.05 - 0.2\text{ mg/kg/hr}$). Bolus $1 - 2\text{ mg}$ IV for breakthrough agitation.
• Disadvantages: Highly lipophilic with active metabolites (1-hydroxymidazolam) that accumulate in adipose tissue and renal impairment, leading to prolonged emergence times and higher rates of ICU delirium. Secondary choice behind propofol or dexmedetomidine.

Dexmedetomidine (Precedex)

• Role: Selective $\alpha_2$-Adrenergic Agonist Sedative.
• Continuous Infusion Dose: $0.2 - 1.5\text{ mcg/kg/hr}$ (Loading boluses of $1.0\text{ mcg/kg}$ over 10 minutes are generally avoided in transport due to transient hypertension followed by severe bradycardia).
• Mechanism: Acts on pre-synaptic $\alpha_2$ receptors in the locus coeruleus to decrease norepinephrine release, producing a unique "cooperative sedation" state where patients remain easily arousable to voice.
• Advantages: No respiratory depression, reduces delirium, opioid-sparing.
• Adverse Effects: Sinus bradycardia and hypotension.

---

Post-Intubation Maintenance Infusion Matrix